-
Performance of drug-coated balloons in coronary and below-the-knee arteries: Anatomical, physiological and pathological considerations Vasc. Pharmacol. (IF 4.0) Pub Date : 2024-03-11 Rafic Ramses, Simon Kennedy, Richard Good, Keith G. Oldroyd, Sean Mcginty
Below-the-knee (infrapopliteal) atherosclerotic disease, which presents as chronic limb-threatening ischemia (CLTI) in nearly 50% of patients, represents a treatment challenge when it comes to the endovascular intervention arm of management. Due to reduced tissue perfusion, patients usually experience pain at rest and atrophic changes correlated to the extent of the compromised perfusion. Unfortunately
-
Challenges with the 4th Universal Definition of Myocardial Infarction – the unsolved issue of Type 2 and the arbitrariness of Type 4 and 5 Vasc. Pharmacol. (IF 4.0) Pub Date : 2024-03-11 Pedro Lopez-Ayala, Raffaele De Caterina, Christian Mueller
-
Angina pectoris 2023: With and without obstructive coronary artery disease: Epidemiology, diagnosis, prognosis, and treatment Vasc. Pharmacol. (IF 4.0) Pub Date : 2024-03-01 Rasha K. Al-Lamee
-
12-week Dolutegravir treatment marginally reduces energy expenditure but does not increase body weight or alter vascular function in a murine model of Human Immunodeficiency Virus infection Vasc. Pharmacol. (IF 4.0) Pub Date : 2024-02-28 Taylor C. Kress, Priscilla Ajala, Coleton R. Jordan, James Mintz, Rodger MacArthur, Simone Kennard, Galina Antonova, Eric J. Belin de Chantemèle
Combination antiretroviral therapy (cART) has markedly increased life expectancy in people with HIV (PWH) but has also resulted in an increased prevalence of cardiometabolic disorders, whose etiopathology remains ill-defined. Notably, the respective contribution of cART and HIV-derived proteins to obesity and vascular alterations remain poorly understood. Therefore, we investigated the individual and
-
Changes in arterial myocyte excitability induced by subarachnoid hemorrhage in a rat model Vasc. Pharmacol. (IF 4.0) Pub Date : 2024-02-24 Gonzalo Revilla-González, Juan Ureña, María del Carmen González-Montelongo, Antonio Castellano
Aneurismal subarachnoid hemorrhage (aSAH) is a neurovascular disease produced by the rupture of the cerebral arteries and the extravasation of blood to the subarachnoid space and is accompanied by severe comorbidities. Secondarily associated vasospasm is one of the main side effects after hydrocephalus and possible rebleeding. Here, we analyze the alterations in function in the arteries of a rat model
-
A critical appreciation of pathway analysis in atherosclerotic disease. Cellular phenotypic plasticity as an illustrative example Vasc. Pharmacol. (IF 4.0) Pub Date : 2024-02-24 M. Wesseling, E. Diez-Benavente, M. Mokry, H.M. den Ruijter, G. Pasterkamp
The rapid advancements in genome-scale (omics) techniques has created significant opportunities to investigate complex disease mechanisms in tissues and cells. Nevertheless, interpreting -omics data can be challenging, and pathway enrichment analysis is a frequently used method to identify candidate molecular pathways that drive gene expression changes. With a growing number of -omics studies dedicated
-
Association of antihypertensive drugs with psoriasis: A trans-ancestry and drug-target Mendelian randomization study Vasc. Pharmacol. (IF 4.0) Pub Date : 2024-02-13 Xiao Xu, Shu-yun Wang, Rongyun Wang, Lin-yun Wu, Min Yan, Zhi-ling Sun, Qiu-hua Sun
-
Immune response following transcatheter aortic valve procedure Vasc. Pharmacol. (IF 4.0) Pub Date : 2024-02-09 Kasra Talebi Anaraki, Zahra Zahed, Roozbeh Narimani Javid, Sasan Shafiei, Fereshteh Beiranvandi, Negin Ghasemi Kahrizsangi, Faraz Golafshan, Alireza Arzhangzade, Javad Kojuri, Samin Almassian, Raha Hadi, Pourya Gholizadeh, Fahimeh Kazeminava
Aortic valve stenosis is the most common type of heart valve disease in the United States and Europe and calcific aortic stenosis (AS) affects 2–7% of people aged 65 years and older. Aortic valve replacement (AVR) is the only effective treatment for individuals with this condition. Transcatheter Aortic Valve Replacement (TAVR) has been widely accepted as a minimally invasive therapeutic approach for
-
Effect of reactive oxygen, nitrogen, and sulfur species on signaling pathways in atherosclerosis Vasc. Pharmacol. (IF 4.0) Pub Date : 2024-02-05 Kundan Solanki, Evgeny Bezsonov, Alexander Orekhov, Suraj P. Parihar, Shivani Vaja, Fletcher A. White, Alexander G. Obukhov, Mirza S. Baig
Atherosclerosis is a chronic inflammatory disease in which fats, lipids, cholesterol, calcium, proliferating smooth muscle cells, and immune cells accumulate in the intima of the large arteries, forming atherosclerotic plaques. A complex interplay of various vascular and immune cells takes place during the initiation and progression of atherosclerosis. Multiple reports indicate that tight control of
-
Adiponectin secretion by perivascular adipose tissue supports impaired vasodilation in a mouse model of accelerated vascular smooth muscle cell and adipose tissue aging Vasc. Pharmacol. (IF 4.0) Pub Date : 2024-02-04 A.A. Jüttner, E. Ataei Ataabadi, K. Golshiri, R. de Vries, I.M. Garrelds, A.H.J. Danser, J.A. Visser, A.J.M. Roks
-
Comparative effectiveness of oral therapies targeting the prostacyclin pathway in pulmonary arterial hypertension: A systematic review and network meta-analysis Vasc. Pharmacol. (IF 4.0) Pub Date : 2024-02-01 Giovanna Manzi, Marco Valerio Mariani, Domenico Filomena, Tommaso Recchioni, Silvia Papa, Gianmarco Scoccia, Roberto Badagliacca, Carmine Dario Vizza
-
COVID-19 plasma induces subcellular remodelling within the pulmonary microvascular endothelium Vasc. Pharmacol. (IF 4.0) Pub Date : 2024-01-23 Rainha Passi, Justyna Cholewa-Waclaw, Ryan Wereski, Matthew Bennett, Stefan Veizades, Bronwyn Berkeley, Andrea Caporali, Ziwen Li, Julie Rodor, Mieke Dewerchin, Nicholas L. Mills, Abdelaziz Beqqali, Mairi Brittan, Andrew H. Baker
-
Doxycycline induces mitochondrial dysfunction in aortic smooth muscle cells Vasc. Pharmacol. (IF 4.0) Pub Date : 2024-01-23 Carmen Yap, Shaynah Wanga, Rob C.I. Wüst, Bram W. van Os, Maud M.E. Pijls, Sofie Keijzer, Eva van Zanten, David R. Koolbergen, Antoine H.G. Driessen, Ron Balm, Kak Khee Yeung, Carlie J.M. de Vries, Riekelt H. Houtkooper, Jan H.N. Lindeman, Vivian de Waard
-
The perspective of cAMP/cGMP signaling and cyclic nucleotide phosphodiesterases in aortic aneurysm and dissection Vasc. Pharmacol. (IF 4.0) Pub Date : 2024-01-21 Ting Shu, Yitian Zhou, Chen Yan
Aortic aneurysm (AA) and dissection (AD) are aortic diseases caused primarily by medial layer degeneration and perivascular inflammation. They are lethal when the rupture happens. Vascular smooth muscle cells (SMCs) play critical roles in the pathogenesis of medial degeneration, characterized by SMC loss and elastin fiber degradation. Many molecular pathways, including cyclic nucleotide signaling,
-
Angiogenesis is promoted by hypoxic cervical carcinoma-derived extracellular vesicles depending on the endothelial cell environment Vasc. Pharmacol. (IF 4.0) Pub Date : 2024-01-17 E. Orozco-García, V. Getova, J.C. Calderón, M.C. Harmsen, R. Narvaez-Sanchez
-
The peripheral corticotropin releasing factor family's role in vasculitis Vasc. Pharmacol. (IF 4.0) Pub Date : 2024-01-04 Chao Zhu, Shengnan Li
-
Myocardial energy balance and metabolism as causes of myocardial ischemia Vasc. Pharmacol. (IF 4.0) Pub Date : 2024-01-04 Mario Marzilli
The current approach to myocardial ischemia has been influenced by the misconception of a close link between ischemia and coronary atherosclerotic obstructions. Recent guidelines have, however, acknowledged the multifactorial nature of this condition, with an identifiable cause present in less than half of angina patients, and a large fraction with angina of unknown origin. Because of this background
-
A treatment algorithm for ischemic cardiomyopathy Vasc. Pharmacol. (IF 4.0) Pub Date : 2024-01-03 Raffaele De Caterina, Riccardo Liga
Treatment of ischemic cardiomyopathy has been the focus of increased attention by cardiologists due to recent evidence of an important outcome study comparing percutaneous coronary intervention (PCI) plus optimal medical treatment vs optimal medical treatment alone, concluding for the futility of myocardial revascularization by PCI. A relatively older trial of coronary artery bypass grafting (CABG)
-
Therapy and guideline adherence at a multidisciplinary hypertension clinic: A prospective, observational study Vasc. Pharmacol. (IF 4.0) Pub Date : 2023-12-28 Julie Hias, Lise Defieuw, Thomas Vanassche, Peter Verhamme, Lorenz Van der Linden
-
Inflammation and the pathogenesis of atherosclerosis Vasc. Pharmacol. (IF 4.0) Pub Date : 2023-12-28 Peter Libby
The notion that inflammation contributes to atherosclerosis has now gained considerable currency. Inflammation participates in atherosclerosis inception, progression, and thrombotic complications. Induced expression of endothelial leukocyte adhesion molecules and chemoattractant cytokines recruit blood cells to the arterial intima. Lesions can contain virtually every type of leukocyte. Monocytes mature
-
Coronary computed tomography angiography vs functional stress imaging to triage chest pain in the emergency room? Vasc. Pharmacol. (IF 4.0) Pub Date : 2023-12-28 Colin Berry
In patients with a suspected acute coronary syndrome, non-elevated (or uncertain) (NSTE-ACS) high sensitivity cardiac troponin, no ECG changes and no recurrence of chest pain, incorporating a coronary computed tomography angiogram (CCTA) or a non-invasive functional stress imaging test as part of the initial workup should be considered (Class IIA, Level of Evidence A). There are pros and cons with
-
Prime editing in mice with an engineered pegRNA Vasc. Pharmacol. (IF 4.0) Pub Date : 2023-12-27 Amr R. Salem, W. Bart Bryant, Jaser Doja, Susan H. Griffin, Xiaofan Shi, Weihong Han, Yunchao Su, Alexander D. Verin, Joseph M. Miano
CRISPR editing involves double-strand breaks in DNA with attending insertions/deletions (indels) that may result in embryonic lethality in mice. The prime editing (PE) platform uses a prime editing guide RNA (pegRNA) and a Cas9 nickase fused to a modified reverse transcriptase to precisely introduce nucleotide substitutions or small indels without the unintended editing associated with DNA double-strand
-
Adipsin in the pathogenesis of cardiovascular diseases Vasc. Pharmacol. (IF 4.0) Pub Date : 2023-12-17 Ayobami Dare, Shi-You Chen
-
Macrophage-mediated downregulation of lncRNA Carmn in mouse abdominal aortic aneurysm Vasc. Pharmacol. (IF 4.0) Pub Date : 2023-12-12 Huan Yang, Ting Zhou, Bo Liu
-
Perivascular and epicardial adipose tissue Vasc. Pharmacol. (IF 4.0) Pub Date : 2023-12-10 Lina Badimon, Gemma Arderiu, Gemma Vilahur, Teresa Padro, Alberto Cordero, Guiomar Mendieta
Abstract not available
-
Optimal medical therapy vs revascularization in chronic coronary syndromes: Does ISCHEMIA move the needle toward or away from revascularization?? Vasc. Pharmacol. (IF 4.0) Pub Date : 2023-12-08 William E. Boden
The optimal management of chronic coronary syndrome (CCS) patients has been a source of debate for several decades. Herein, we describe the evidence base comprising several landmark clinical trials including the most recent ISCHEMIA Trial, which, in aggregate, does not demonstrate a conclusive, incremental benefit of revascularization combined with optimal medical therapy (OMT) versus OMT alone in
-
Two sides of the same coin: Non-alcoholic fatty liver disease and atherosclerosis Vasc. Pharmacol. (IF 4.0) Pub Date : 2023-12-07 Bo Zhu, Hao Wu, Kathryn S. Li, Shahram Eisa-Beygi, Bandana Singh, Diane R. Bielenberg, Wendong Huang, Hong Chen
-
Flow Mediated Dilation in Systemic Sclerosis: Association with clinical findings, capillaroscopic patterns and endothelial circulating markers Vasc. Pharmacol. (IF 4.0) Pub Date : 2023-12-06 Addolorata Corrado, Natalia Mansueto, Michele Correale, Valeria Rella, Lucia Tricarico, Alberto Altomare, Natale Daniele Brunetti, Francesco Paolo Cantatore, Cinzia Rotondo
-
Unvealing organ-specific endothelial heterogeneity and its dysfunction Vasc. Pharmacol. (IF 4.0) Pub Date : 2023-12-01 Rosalinda Madonna
Abstract not available
-
Activated CTHRC1 promotes glycolysis in endothelial cells: Implications for metabolism and angiogenesis Vasc. Pharmacol. (IF 4.0) Pub Date : 2023-11-29 Barbara H. Toomey, Sarah A. Mitrovic, Maia Lindner-Liaw, Ruth G. Leon Vazquez, Doreen Kacer, Sergey Ryzhov, Igor Prudovsky, Volkhard Lindner
-
The hydroxamic acid derivative YPX-C-05 alleviates hypertension and vascular dysfunction through the PI3K/Akt/eNOS pathway Vasc. Pharmacol. (IF 4.0) Pub Date : 2023-12-03 Pan-Pan Pang, Hao Sun, Pei-xia Yu, Wei-min Yang, Yong-Tang Zheng, Xun Li, Chang-Bo Zheng
-
Sex differences in vascular endothelial function related to acute and long COVID-19 Vasc. Pharmacol. (IF 4.0) Pub Date : 2023-12-02 Kayla Kitselman A, Jérôme Bédard-Matteau, Simon Rousseau, Reza Tabrizchi, Noriko Daneshtalab
-
Contemporary anticoagulant treatment strategies in patients with acute pulmonary embolism at different risk for death Vasc. Pharmacol. (IF 4.0) Pub Date : 2023-11-25 Cecilia Becattini, Giancarlo Agnelli, Michele Diamanti, Aldo P. Maggioni, Simone Vanni, Francesco Dentali, Iolanda Enea, Paola Bortolotti, Massimiliano De Vecchi, Nicola Artusi, Claudio Picariello, Cinzia Nitti, Donata Lucci, Michele M. Gulizia
-
Diabetes and vascular disease: New therapeutic avenues Vasc. Pharmacol. (IF 4.0) Pub Date : 2023-11-28 Stefano Del Prato
-
Efficacy and safety of tirofiban in patients with acute ischemic stroke treated with endovascular thrombectomy: A frequentist and Bayesian meta-analysis Vasc. Pharmacol. (IF 4.0) Pub Date : 2023-11-21 Wei-Zhen Lu, Hui-An Lin, Sen-Kuang Hou, Chyi-Huey Bai, Sheng-Feng Lin
-
MINOCA: Diagnostic work-up, risk stratification and tailored therapies Vasc. Pharmacol. (IF 4.0) Pub Date : 2023-11-14 C. Noel Bairey Merz, Martha Gulati, Janet Wei
-
Endothelial heterogeneity and their relevance in cardiac development and coronary artery disease Vasc. Pharmacol. (IF 4.0) Pub Date : 2023-11-07 Rosalinda Madonna
-
Tissue-specific Cre driver mice to study vascular diseases Vasc. Pharmacol. (IF 4.0) Pub Date : 2023-11-03 Qing Rex Lyu, Kailong Fu
-
Pathophysiology of coronary microvascular dysfunction Vasc. Pharmacol. (IF 4.0) Pub Date : 2023-10-28 Filippo Crea, Rocco A. Montone
The term “coronary microvascular dysfunction” (CMD) encompasses several pathogenetic mechanisms resulting in functional and/or structural changes in the coronary microcirculation. CMD often determines angina and myocardial ischemia in a broad spectrum of cardiovascular diseases, including patients with ischemia with non-obstructive coronary arteries or ischemia with obstructive coronary artery disease
-
Plaque histological characteristics in individuals with sudden coronary death Vasc. Pharmacol. (IF 4.0) Pub Date : 2023-10-28 Takao Konishi, Renu Virmani, Hiroyuki Jinnouchi, Kenji Kawai, Teruo Sekimoto, Rika Kawakami, Aloke V. Finn
Coronary artery disease (CAD) remains the leading cause of death in the Western world in individuals >20 years of age. CAD is the most common substrate underlying sudden cardiac death (SCD) in the Western world, being responsible for 50–75% of SCDs. In individuals dying suddenly with coronary thrombosis, plaque rupture occurs in 65%, plaque erosion in 30% and calcified nodule in 5%. We evaluated the
-
Targeting residual inflammatory risk: The next frontier for atherosclerosis treatment and prevention Vasc. Pharmacol. (IF 4.0) Pub Date : 2023-10-21 Paul M Ridker
Inflammation and hyperlipidemia act synergistically to drive atherosclerotic progression. Multiple randomized trials now demonstrate that “lower is better” not only for LDLC, but also for hsCRP. Recent data among statin treated patients indicates that residual inflammatory risk is a stronger determinant of recurrent events than residual cholesterol risk. Based on trial data demonstrating a 31% reduction
-
Animal experimental models of ischemic limbs – A systematic review Vasc. Pharmacol. (IF 4.0) Pub Date : 2023-10-05 Veronika Lovasova, Robert Bem, Jaroslav Chlupac, Michal Dubsky, Jitka Husakova, Andrea Nemcova, Jiri Fronek
-
Global and endothelial G-protein coupled receptor 75 (GPR75) knockout relaxes pulmonary artery and mitigates hypoxia-induced pulmonary hypertension Vasc. Pharmacol. (IF 4.0) Pub Date : 2023-09-23 Catherine A. D'Addario, Shun Matsumura, Atsushi Kitagawa, Gregg M. Lainer, Frank Zhang, Melinee D'silva, Mohammad Y. Khan, Ghezal Froogh, Artiom Gruzdev, Darryl C. Zeldin, Michal L. Schwartzman, Sachin A. Gupte
-
Activation of BMP4-pSmad1/5 pathway impairs the function of VSMCs in intracranial aneurysms Vasc. Pharmacol. (IF 4.0) Pub Date : 2023-09-27 Luojiang Zhu, Haishuang Tang, Congyan Wu, Yanpeng Wei, Qiang Li, Dongwei Dai, Pengfei Yang, Qinghai Huang, Yi Xu, Jianmin Liu, Rui Zhao, Qiao Zuo
-
Heterogeneous vasomotor responses in segments from Göttingen Minipigs coronary, cerebral, and mesenteric artery: A comparative study Vasc. Pharmacol. (IF 4.0) Pub Date : 2023-09-18 Anette Sams, Kristian Agmund Haanes, Anja Holm, Spyridoula Kazantzi, Lars Friis Mikkelsen, Lars Edvinsson, Susan Brain, Majid Sheykhzade
-
Therapeutic potential and protective role of GRK6 overexpression in pulmonary arterial hypertension Vasc. Pharmacol. (IF 4.0) Pub Date : 2023-09-22 Chenchen Liu, Naifu Wan, Lijiang Wei, Wuwei Rong, Wentong Zhu, Meifeng Xie, Yanling Zhang, Zhihua Liu, Qing Jing, Ankang Lyu
-
Optimising antithrombotic therapy after ACS and PCI Vasc. Pharmacol. (IF 4.0) Pub Date : 2023-09-17 Davide Capodanno
Dual antiplatelet therapy, combining aspirin with a platelet P2Y12 receptor inhibitor, is the standard treatment for acute coronary syndrome patients undergoing percutaneous coronary intervention. The optimal type and duration of dual antiplatelet therapy depend on the patient's risk for ischemic and hemorrhagic complications. De-escalation strategies, such as switching to a less potent P2Y12 inhibitor
-
Roles of endothelial and smooth muscle cell dysfunction and vasa vasorum in vasomotor disorders in ischemia with no obstructive coronary artery disease Vasc. Pharmacol. (IF 4.0) Pub Date : 2023-09-21 Hiroaki Shimokawa
Recently, the importance has emerged of ischemia with no obstructive coronary artery disease (INOCA), for which endothelial and vascular smooth muscle cell (VSMC) dysfunctions and alterations in coronary vasa vasorum are involved. Regarding endothelial vasodilator functions, both endothelium-derived nitric oxide and endothelium-derived hyperpolarizing factor play important roles in modulating vascular
-
The MEK-ERK-Egr-1 axis and its regulation in cardiovascular disease Vasc. Pharmacol. (IF 4.0) Pub Date : 2023-09-20 Levon M. Khachigian
Cardiovascular disease (CVD) is the primary cause of morbidity and mortality in the Western world. Multiple molecular and cellular processes underpinning the pathogenesis of CVD are regulated by the zinc finger transcription factor and product of an immediate-early gene, early growth response-1 (Egr-1). Egr-1 regulates multiple pro-inflammatory processes that underpin the manifestation of CVD. The
-
Hypertension, coronary artery disease and myocardial ischemic syndromes Vasc. Pharmacol. (IF 4.0) Pub Date : 2023-09-20 Massimo Volpe, Giovanna Gallo
-
Emerging therapies in dyslipidaemias Vasc. Pharmacol. (IF 4.0) Pub Date : 2023-09-15 Alberico L. Catapano
-
MicroRNAs and their regulators: Potential therapeutic targets in pulmonary arterial hypertension Vasc. Pharmacol. (IF 4.0) Pub Date : 2023-09-10 Yang-Zhi-Ge He, Yi-Xuan Wang, Jing-Si Ma, Ruo-Nan Li, Jia Wang, Tian-Yu Lian, Yu-Ping Zhou, Hao-Pu Yang, Kai Sun, Zhi-Cheng Jing
-
Antineoplastic drugs inducing cardiac and vascular toxicity – An update Vasc. Pharmacol. (IF 4.0) Pub Date : 2023-09-08 Serena Barachini, Sandra Ghelardoni, Zoltán V. Varga, Radwa A. Mehanna, Maria Magdalena Montt-Guevara, Péter Ferdinandy, Rosalinda Madonna
-
-
-
-
Antibody-mediated PCSK9 neutralization worsens outcome after bare-metal stent implantation in mice Vasc. Pharmacol. (IF 4.0) Pub Date : 2023-08-31 Yustina M. Puspitasari, Stefano Ministrini, Luca Liberale, Ana Vukolic, Philine Baumann-Zumstein, Erik W. Holy, Fabrizio Montecucco, Thomas F. Lüscher, Giovanni G. Camici
-
Circulating soluble IL-6 receptor associates with plaque inflammation but not with atherosclerosis severity and cardiovascular risk Vasc. Pharmacol. (IF 4.0) Pub Date : 2023-08-25 Andreas Edsfeldt, Isabel Gonçalves, Isa Vigren, Anja Jovanović, Gunnar Engström, Angela C. Shore, Andrea Natali, Faisel Khan, Jan Nilsson
-
Insights into elastin fiber fragmentation: Mechanisms and treatment of aortic aneurysm in Marfan syndrome Vasc. Pharmacol. (IF 4.0) Pub Date : 2023-08-26 Sheilabi Seeburun, Shichao Wu, Darshi Hemani, Lucynda Pham, Donghong Ju, Youming Xie, Priyaranjan Kata, Li Li
-
Exploring the significance of epicardial adipose tissue in aortic valve stenosis and left ventricular remodeling: Unveiling novel therapeutic and prognostic markers of disease Vasc. Pharmacol. (IF 4.0) Pub Date : 2023-08-21 Stefano Quarta, Giuseppe Santarpino, Maria Annunziata Carluccio, Nadia Calabriso, Michele Maffia, Luisa Siculella, Fabrizio Damiano, Rosalinda Madonna, Marika Massaro